A Biacore T200 for Molecular Interaction Studies at the University of Miami
A Biacore T200 for Molecular Interaction Studies at the University of Miami
批准号:
8247257
负责人:
RALF LANDGRAF
金额:
$35.1万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2013-03-31
关键词:
AntibodiesApplied ResearchBasic ScienceBindingClinical ResearchComprehensive Cancer CenterDNADetectionEquipmentEvaluationFloridaFosteringFundingFutureHealthHousingHumanInstitutesLabelLeadMaintenanceMeasurementMedicalMethodsModalityMolecular WeightNucleic AcidsOutsourcingPTPRC genePharmaceutical PreparationsPropertyProteinsRadialResearchResearch PersonnelSamplingSerumStructureSurface Plasmon ResonanceThermodynamicsUnited States National Institutes of HealthUniversitiesaptamerfallsimprovedinstrumentinstrumentationmedical schoolsnovelprotein complexpublic health relevancesmall molecule
中文摘要
描述(由申请人提供):迈阿密大学米勒医学院的六个基础研究部门开展了广泛的基础科学研究,具有很强的转化成分。跨部门的结构,如综合癌症中心(有助于维护拟议的SPR设备)促进基础研究人员和临床研究小组之间的互动。在这一研究人员组合组(包括一个用户从邻近的佛罗里达斯克里普斯研究所),一个强烈的需要存在的模式,允许高灵敏度和标记自由分子相互作用的研究与小样本量。在过去的十年中,表面等离子体共振已经成为这类应用的主要(如果不是占主导地位的话)分析方法,特别是近年来其灵敏度的增加(现在包括小分子分析物的无标记结合研究)以及多重和自动测量的能力。这允许以最小的样品体积有效地进行广泛的研究。我们对SPR能力的高需求与UM数百英里半径内没有任何开放访问的此类设备形成鲜明对比。SPR能力的缺乏迫使研究人员最多依赖于不太敏感和信息量较少的方法。在某些情况下,这种新型小分子先导化合物的无标记结合,没有其他选择可用。在其他情况下(抗体优化),外包是目前唯一的选择
拟议购买的Biacore T200将在UM校园建立急需的SPR能力。该仪器将被安置在一个受监督的仪器设施中,并将通过机构支持进行维护。特色应用包括治疗用抗体的表征和优化,现有或从头合成的小分子量药物的评估,ITC和SPR作为替代方法之间热力学结合性质的详细比较,DNA上多蛋白复合物的组装,SELEX衍生核酸适体与靶蛋白的表征,和血清样品中分析物浓度的检测,以及几个强调SPR在弱相互作用研究中的优势的项目所有应用都在Biacore T200的能力范围内,SPR的可用性肯定会促进现有和未来NIH资助的研究的进展。
公共卫生相关性:访问表面等离子体共振将加速现有的,并开辟了新的研究应用在整个医学校园的UM。受影响的项目范围从非常基础的应用研究到具有直接转化潜力的应用研究。因此,我们期望对旨在改善人类健康的研究产生高度协同影响。
英文摘要
DESCRIPTION (provided by applicant): The six basic research departments at the University of Miami, Miller School of Medicine carry out a broad range of basic science studies with strong translational components. Interdepartmental structures like the Comprehensive Cancer Center (which contributes to the maintenance of the proposed SPR equipment) foster interactions between basic researchers and with clinical research groups. Among this combined group of researchers (including one user from the neighboring Florida Scripps Institute), a strong need exists for modalities that allow highly sensitive and label free molecular interaction studies with small sample volumes. Surface Plasmon Resonance has become a major, if not the dominant, method of analysis for this type of applications in the last decade, especially with its increase in sensitivity in recent years (which now includes the label free binding studies of small molecule analytes) and the ability to multiplex and automate measurements. This allows for a broad range of studies to be carried out efficiently and with minimal sample volumes. Our high demand for SPR capability is in stark contrast to the absence of any such equipment with open access within a several hundred mile radius of UM. The absence of SPR capability forces researchers to rely on less sensitive and less informative methods at best. In some cases, such label free binding of novel, small molecule lead compounds, no other options are available. In yet other cases (antibody optimization) outsourcing is currently the only option
The proposed purchase of a Biacore T200 would establish much needed SPR capability on the UM campus. The instrument will be housed in a supervised instrumentation facility will be maintained through institutional support. Featured applications include the characterization and optimization of therapeutically used antibodies, the evaluation of existing or de novo synthesized small molecular weight drugs, the detailed comparison of thermodynamic binding properties between ITC and SPR as alternative methods, the assembly of multi protein complexes on DNA, the characterization of SELEX derived nucleic acid aptamers to target proteins, and the detection of analyte concentrations in serum samples, and several projects emphasizing the strength of SPR in the study of weak interactions All applications fall within the capability range of a Biacore T200, and availability of SPR is certain to enhance progress on existing and future NIH-funded research.
Public Health Relevance: Access to Surface Plasmon Resonance will accelerate existing and open up new research applications across the medical campus of UM. The impacted projects range from very basic to applied research with immediate translational potential. We therefore expect a highly synergistic impact on studies aimed at improving human health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin Resistance
-
批准号:10377576
-
项目类别:
-
资助金额:$47.05万
-
财政年份:2019
-
负责人:RALF LANDGRAF
-
依托单位:
Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin Resistance
-
批准号:9906184
-
项目类别:
-
资助金额:$49.1万
-
财政年份:2019
-
负责人:RALF LANDGRAF
-
依托单位:
Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin Resistance
-
批准号:10595082
-
项目类别:
-
资助金额:$47.05万
-
财政年份:2019
-
负责人:RALF LANDGRAF
-
依托单位:
Role and Mechanism of HER2 Self-Association in Cancer
-
批准号:6913683
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Role and Mechanism of HER2 Self-Association in Cancer
-
批准号:6679356
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:7500315
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Role and Mechanism of HER2 Self-Association in Cancer
-
批准号:7072634
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:8510001
-
项目类别:
-
资助金额:$1.19万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Role and Mechanism of HER2 Self-Association in Cancer
-
批准号:6767575
-
项目类别:
-
资助金额:$27.32万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:7375348
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:8497787
-
项目类别:
-
资助金额:$2.75万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:8298623
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:7924619
-
项目类别:
-
资助金额:$4.77万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:7690807
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
Rewiring ERBB Signaling in Cancer Cells
-
批准号:8132797
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2003
-
负责人:RALF LANDGRAF
-
依托单位:
UNDERSTANDING AND REDEFNING NEUREGULIN SPECIFICITY
-
批准号:6087551
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1999
-
负责人:RALF LANDGRAF
-
依托单位:
UNDERSTANDING AND REDEFNING NEUREGULIN SPECIFICITY
-
批准号:2002910
-
项目类别:
-
资助金额:$2.96万
-
财政年份:1998
-
负责人:RALF LANDGRAF
-
依托单位:
UNDERSTANDING AND REDEFNING NEUREGULIN SPECIFICITY
-
批准号:2824456
-
项目类别:
-
资助金额:$3.84万
-
财政年份:1998
-
负责人:RALF LANDGRAF
-
依托单位:
海外基金